Indolent T-Cell Non-Hodgkin Lymphoma — Trials

Indolent T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

134 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: City of Hope Medical Center
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05838599	Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides	recruiting	Early Phase 1	25	Northwestern UniversityOTHER	1	May 1, 2026	clinicaltrials
NCT07213882	A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY)	not yet recruiting	Early Phase 1	30	Assistance Publique - Hôpitaux de ParisOTHER